Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28888490 | 0.89 | DRD2 (0.40) | DRD2DRD3SLC6A3DRD4 | |
| SCHEMBL671899 | 0.83 | APP (0.44) | TP53SMN1; SMN2 | |
| SCHEMBL28615816 | 0.83 | TP53 (0.36) | DRD2DRD4TP53SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL9295903 | 0.81 | APP (0.42) | TP53SMN1; SMN2 | |
| Sulfuric Acid SCHEMBL28066027 | 0.81 | PIK3CD (0.42) | DRD2DRD3SLC6A3DRD4 | |
| SCHEMBL4352917 | 0.80 | PAOX (0.48) | TP53 | |
| Sulfuric Acid SCHEMBL3975431 | 0.79 | LMNA (0.49) | DRD2DRD3SLC6A3DRD4 | |
| SCHEMBL8742874 | 0.78 | KDM4E (0.39) | — | |
| SCHEMBL4022137 | 0.77 | APP (0.42) | DRD2DRD3 | |
| SCHEMBL17493164 | 0.76 | MEN1 (0.46) | DRD2DRD3SLC6A3DRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204065-A1 | IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-29 | — | — | WO | disclosed |
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2020102820-A1 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | DRD2 1271/4885DRD3 1028/4885SLC6A3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.